The US Food and Drug Administration has approved a blood diagnostics device developed by ANGLE PLC (AIM:AGL, OTCQX:ANPCY) that can identify metastatic breast cancer in patients.
UK-based biotech company Angle’s Parsortix technology is the first product ever to be cleared by US regulators that harvests cancer cells from a blood sample.
Atlantic Lithium Limited (AIM:ALL), which is developing the Ewoyaa lithium project in Ghana, has confirmed that it was approached by Ghana’s Minerals Income Investment Fund, and accordingly has signed a non-disclosure agreement
The NDA allows the two parties to enter into discussions regarding a potential investment into the company from the MIIF, although at this stage no discussions have yet occurred.
ANGLE PLC (AIM:AGL, OTCQX:ANPCY) has scored a world first by achieving US Food & Drug Administration clearance for its Parsortix liquid biopsy system – a technology that is able to harvest cancer cells from a simple blood sample.
The company reckons the De Novo approval from the American regulator heralds a new era for personalised cancer care.
Genflow Biosciences PLC (LSE:GENF) told investors it has filed international patent applications related to variants of Sirtuin-6 (SIRT 6) and the gene variant's therapeutic uses in the regulation of aging and for the treatment and prevention of age-related diseases.
The patents applications are filed in the US under the Patent Cooperation Treaty (PCT), it noted.
Endeavour Mining PLC (LSE:EDV, TSX:EDV, OTCQX:EDVMF), the largest gold producer in West Africa, has published its 2021 sustainability report with key environmental, social and governance (ESG) highlights.
The company said its total economic contribution to host countries doubled over the prior year to U$2.0bn. Around 80% of its total procurement was in-country, while 95% of its workforce, and almost half of its senior operational management, are nationals.
ImmuPharma PLC (AIM:IMM, OTC:IMMPF) hailed its recent progress as it said major roadblocks to clinical progress had been effectively cleared.
In an update alongside full-year results, it confirmed US partner, Avion Pharmaceuticals, is committed to taking lead asset Lupuzor into phase III clinical trials after the successful completion of a pharmacokinetic study mandated by the US regulator.
SEED Innovations Ltd (AIM:SEED, OTC:FFRIF) said investee company Yooma Wellness Inc. has been reinstated for trading on the Canadian Securities Exchange with immediate effect. SEED has a holding of approximately 4.4% of Yooma's issued share capital.